Professor Peter McIntyre



School /
Work Unit

School of Health and Biomedical Sciences

Contact Details

+61 3 9925 7085


Building: 223
Level: 02
Room: 002

Bundoora West campus


Science, Engineering and Health

Peter McIntyre staff profile image

Key activities

  • 2012 Deputy Director, Health Innovations Research Institute (HIRi)
  • 2013 Chair, Institutional Biosafety Committee


  • B. Sc. (Hons), LaTrobe University, 1980
  • PhD (Biochemistry and Molecular Biology), LaTrobe University, 1985

Industry experience

Industry and community involvement

  • Member of the:
    • Australian Society of Clinical and Basic Pharmacologists and Toxicologists (ASCEPT)
    • Society for Neuroscience (USA)
    • International Society for the Study of Pain
    • American Society for Biochemistry and Molecular Biology.
  • Member of the:
    • APHRA Optometry Board
    • Scheduled Medicines Advisory Committee
  • RMIT University representative on Research Australia University Roundtable
  • 2009-2012 Elected ASCEPT Councillor
  • Former Section Head and Drug Discovery group leader at Novartis Institutes for Medical Research, University College, London
  • 1989-1996 Senior Scientist, Sandoz Pharmaceuticals, London
  • 1996-2005 Group Leader and Section Head, Novartis Neuroscience, London

Projects and consultancies (Current)

  • 2013-2015 CIA NHMRC Project grant APP1046860
    “Targeting TRPV4 activation mechanisms to reveal novel pain therapies”
  • 2012-2014 CIC NHMRC Project grant APP1031886
    “Bile acid and Neurosteroid Signaling to the Nervous System”
  • 2011-2013 CIB NHMRC Project grant APP1025715
    “The calcium channel TRPV4 in skeletal development and arthritis”
  • 2010-2014 CIB NHMRC Project grant APP1002680
    “Molecular targets of amino acid/ neurotransmitter conjugates of fatty acids”

Teaching responsibilities

  • 2010-current Postgraduate medical course, University of Melbourne
  • 2007-2009 Honours Coordinator, Department of Pharmacology, university of Melbourne
  • 2006-2012 2nd and 3rd year Pharmacology, University of Melbourne
  • 2005-2010 Head of Department of Pharmacology, University of Melbourne

Educational development work

  • Participated in development of the postgraduate medical curriculum, University of Melbourne


  • 2003 Novartis Neuroscience Award
  • 1986-1989 Imperial Cancer research Fund Postdoctoral Fellowship
  • 1985-1986 MacArthur Foundation Fellow
  • 1981-1985 Commonwealth Postgraduate Award

Research interests

Peter McIntyre is a molecular pharmacologist with a longstanding interest in the mechanisms of chronic pain. He has worked in an international pharmaceutical research organisation at senior levels for many years prior to moving into academia. He has significant experience in pharma drug discovery, having headed project groups looking for new painkilling drugs that inhibit the pain-related ion channel that is the “chili-pepper receptor”, TRPV1. He participated in the discovery of the sensory TRP ion channels TRPM8, TRPA1 and TRPM8 and has been involved in drug discovery teams that tested five new chemical entities in phase 1 and phase 2 clinical trials. He is currently investigating the way in which cell surface receptors signal to ion channels to send signals. He focuses on TRPV and TRPA ion channel families, which are important for sensing environmental signals and for homeostatic mechanisms in mammals.


Research publications since 1997

  • Christie AF, Dent C, McIntyre P, Wilson L, Studdert DM. Patents Associated with High-Cost Drugs in Australia. PLOSone. 2013 Mar 19;:1–7.
  • Poole DP, Amadesi S, Veldhuis NA, Abogadie FC, Lieu T, Darby W, et al. Protease-activated Receptor 2 (PAR2) Protein and Transient Receptor Potential Vanilloid 4 (TRPV4) Protein Coupling Is Required for Sustained Inflammatory Signaling. Journal of Biological Chemistry. 2013 Feb 22;288(8):5790–802.
  • Veldhuis NA, Lew MJ, Abogadie FC, Poole DP, Jennings EA, Ivanusic JJ, et al. N-Glycosylation Determines Ionic Permeability and Desensitization of the TRPV1 Capsaicin Receptor. J. Biol. Chem. 2012 Jun 22;287(26):21765–72.
  • Nash MS, McIntyre P, Groarke A, Lilley E, Culshaw A, Hallett A, et al. 7-tert-Butyl-6-(4-Chloro-Phenyl)-2-Thioxo-2,3-Dihydro-1H-Pyrido[2,3-d]Pyrimidin-4-One, a Classic Polymodal Inhibitor of Transient Receptor Potential Vanilloid Type 1 with a Reduced Liability for Hyperthermia, Is Analgesic and Ameliorates Visceral Hypersensitivity. J. Pharmacol. Exp. Ther. 2012 Aug;342(2):389–98.
  • Callaghan B, Hunne B, Hirayama H, Sartor DM, Nguyen TV, Abogadie FC, et al. Sites of action of ghrelin receptor ligands in cardiovascular control. AJP: Heart and Circulatory Physiology. 2012 Oct 15;303(8):H1011–21.
  • Lamandé SR, Yuan Y, Gresshoff IL, Rowley L, Belluoccio D, Kaluarachchi K, et al. Mutations in TRPV4 cause an inherited arthropathy of hands and feet. Nat. Genet. 2011 Nov;43(11):1142–6.
  • Gibbs GM, ORTA G, Reddy T, Koppers AJ, Martinez-Lopez P, Luis de la Vega-Beltran J, et al. Cysteine-rich secretory protein 4 is an inhibitor of transient receptor potential M8 with a role in establishing sperm function. Proceedings of the National Academy of Sciences. 2011 ed. 2011 Apr 26;108(17):7034–9.
  • Koppers AJ, Gibbs GM, Reddy T, McIntyre P, O'Bryan MK. Role of CRISP4 in ion channel regulation and male reproduction. Reproduction, Fertility and Development. CSIRO; 2010;22(9):100–0.
  • Cromer BA, McIntyre P. Painful toxins acting at TRPV1. Toxicon. 2008 Feb;51(2):163–73.
  • Culshaw AJ, Bevan S, Christiansen M, Copp P, Davis A, Davis C, et al. Identification and biological characterization of 6-aryl-7-isopropylquinazolinones as novel TRPV1 antagonists that are effective in models of chronic pain. J. Med. Chem. 2006 ed. 2006 Jan 26;49(2):471–4.
  • Dragoni I, Guida E, McIntyre P. The cold and menthol receptor TRPM8 contains a functionally important double cysteine motif. J. Biol. Chem. 2006 Dec 8;281(49):37353–60.
  • Fox A, Kaur S, Li B, Panesar M, Saha U, Davis C, et al. Antihyperalgesic activity of a novel nonpeptide bradykinin B1 receptor antagonist in transgenic mice expressing the human B1 receptor. British Journal of Pharmacology. 2005 ed. 2005 Apr;144(7):889–99.
  • Wotherspoon G, Fox A, McIntyre P, Colley S, Bevan S, Winter J. Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. NSC. 2005;135(1):235–45.
  • Phillips E, Reeve A, Bevan S, McIntyre P. Identification of species-specific determinants of the action of the antagonist capsazepine and the agonist PPAHV on TRPV1. J. Biol. Chem. 2004 Apr 23;279(17):17165–72.
  • Ritchie TJ, Dziadulewicz EK, Culshaw AJ, Muller W, Burgess GM, Bloomfield GC, et al. Potent and orally bioavailable non-peptide antagonists at the human bradykinin B(1) receptor based on a 2-alkylamino-5-sulfamoylbenzamide core. J. Med. Chem. 2004 Sep 9;47(19):4642–4.
  • Story GM, Peier AM, Reeve AJ, Eid SR, Mosbacher J, Hricik TR, et al. ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell. 2003 Mar 21;112(6):819–29.
  • Walker KM, Urban L, Medhurst SJ, Patel S, Panesar M, Fox AJ, et al. The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain. J. Pharmacol. Exp. Ther. 2003 Jan;304(1):56–62.
  • Peier AM, Reeve AJ, Andersson DA, Moqrich A, Earley TJ, Hergarden AC, et al. A heat-sensitive TRP channel expressed in keratinocytes. Science. 2002 Jun 14;296(5575):2046–9.
  • Peier AM, Moqrich A, Hergarden AC, Reeve AJ, Andersson DA, Story GM, et al. A TRP channel that senses cold stimuli and menthol. Cell. 2002 Mar 8;108(5):705–15.
  • Savidge J, Davis C, Shah K, Colley S, Phillips E, Ranasinghe S, et al. Cloning and functional characterization of the guinea pig vanilloid receptor 1. Neuropharmacology. 2002 Sep;43(3):450–6.
  • Wibulswas A, Croft D, Pitsillides AA, Bacarese-Hamilton I, McIntyre P, Genot E, et al. Influence of epitopes CD44v3 and CD44v6 in the invasive behavior of fibroblast-like synoviocytes derived from rheumatoid arthritic joints. Arthritis & Rheumatism. 2002 Aug;46(8):2059–64.
  • Dziadulewicz EK, Ritchie TJ, Hallett A, Snell CR, Davies JW, Wrigglesworth R, et al. Nonpeptide bradykinin B2 receptor antagonists: conversion of rodent-selective bradyzide analogues into potent, orally-active human bradykinin B2 receptor antagonists. J. Med. Chem. 2002 May 23;45(11):2160–72.
  • McIntyre P, McLatchie LM, Chambers A, Phillips E, Clarke M, Savidge J, et al. Pharmacological differences between the human and rat vanilloid receptor 1 (VR1). British Journal of Pharmacology. 2001 Mar;132(5):1084–94.
  • Burgess GM, Perkins MN, Rang HP, Campbell EA, Brown MC, McIntyre P, et al. Bradyzide, a potent non-peptide B(2) bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesia. British Journal of Pharmacology. 2000 Jan;129(1):77–86.
  • Haddad EB, Fox AJ, Rousell J, Burgess G, McIntyre P, Barnes PJ, et al. Post-transcriptional regulation of bradykinin B1 and B2 receptor gene expression in human lung fibroblasts by tumor necrosis factor-alpha: modulation by dexamethasone. Molecular Pharmacology. 2000 Jun;57(6):1123–31.
  • Phagoo SB, Yaqoob M, Herrera-Martinez E, McIntyre P, Jones C, Burgess GM. Regulation of bradykinin receptor gene expression in human lung fibroblasts. European Journal of Pharmacology. 2000 Jun 2;397(2-3):237–46.
  • Wibulswas A, Croft D, Bacarese-Hamilton I, McIntyre P, Genot E, Kramer IM. The CD44v7/8 epitope as a target to restrain proliferation of fibroblast-like synoviocytes in rheumatoid arthritis. The American journal of pathology. 2000 Dec;157(6):2037–44.
  • Ogun-Muyiwa P, Helliwell R, McIntyre P, Winter J. Glial cell line derived neurotrophic factor (GDNF) regulates VR1 and substance P in cultured sensory neurons. NeuroReport. 1999 Jul 13;10(10):2107–11.
  • Jones C, Phillips E, Davis C, Arbuckle J, Yaqoob M, Burgess GM, et al. Molecular characterisation of cloned bradykinin B1 receptors from rat and human. European Journal of Pharmacology. 1999 Jun 25;374(3):423–33.
  • Croft D, McIntyre P, Wibulswas A, Kramer I. Sustained elevated levels of VCAM-1 in cultured fibroblast-like synoviocytes can be achieved by TNF-alpha in combination with either IL-4 or IL-13 through increased mRNA stability. The American journal of pathology. 1999 Apr;154(4):1149–58.
  • Helliwell RJ, McLatchie LM, Clarke M, Winter J, Bevan S, McIntyre P. Capsaicin sensitivity is associated with the expression of the vanilloid (capsaicin) receptor (VR1) mRNA in adult rat sensory ganglia. Neuroscience Letters. 1998 Jul 10;250(3):177–80.
  • Walpole CS, Brown MC, James IF, Campbell EA, McIntyre P, Docherty R, et al. Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist. British Journal of Pharmacology. 1998 May;124(1):83–92.
  • Croft DR, Dall P, Davies D, Jackson DG, McIntyre P, Kramer IM. Complex CD44 splicing combinations in synovial fibroblasts from arthritic joints. European journal of immunology. 1997 Jul;27(7):1680–4.
  • Phagoo SB, Yaqoob M, McIntyre P, Jones C, Burgess GM. Cytokines increase B1 bradykinin receptor mRNA and protein levels in human lung fibroblasts. Biochemical Society transactions. 1997 Feb;25(1):43S.


  • Patent: V1_3695557: AUSTRALIA, 2011
    Status: Applied for (Provisional)
    Registered in names of (Inventors): Peter McIntyre
    Description of patent: Patent covering the use of Lyn kinase inhibitors for the treatment of pain due to TRPV4 activation.
  • Patent: US 7,638,601 B2: UNITED STATES OF AMERICA, 2009
    Status: Granted
    Registered in names of (Inventors): Stuart Bevan, Pamposh Ganju, Peter McIntyre, Ardem Patapoutian, Andrea Peier and Chuanzheng Song
    Description of patent: Cloning and use of TRPM8 ion channel.
  • Patent: US 7,396,910 B2: UNITED STATES OF AMERICA, 2008
    Status: Granted
    Registered in names of (Inventors): Bevan S, Ganju P, McIntyre P, Patapoutian A, Peier A, Song C
    Description of patent: Transient receptor channel TRPV3 and its use.
  • Patent: CA 2450113: CANADA, 2007
    Status: Under Examination
    Registered in names of (Inventors): Patapoutian A, Song C, Ganju P, Peier A, McIntyre P, Bevan S.
    Description of patent: This invention provides novel genes and polypeptides of the TRP family, identification of trkA+ pain specific genes expressed inthe DRG, and use of these genes and polypeptides for the treatment of pain and identification of agents useful in the treatment of pain.
  • Patent: US 7,115,414 B2: UNITED STATES OF AMERICA, 2006
    Status: Granted
    Registered in names of (Inventors): Bevan S, Ganju P, McIntyre P, Patapoutian A, Peier A, Song C
    Description of patent: Vanilloid receptor -related nucleic acids and peptides.
  • Patent: AU 2006252263: AUSTRALIA, 2006
    Status: Under Examination
    Registered in names of (Inventors): Patapoutian A, Song C, Ganju P, Peier A, McIntyre P, Bevan S.
    Description of patent: This invention provides novel genes and polypeptides of the TRP family, identification of trkA+ pain specific genes expressed inthe DRG, and use of these genes and polypeptides for the treatment of pain and identification of agents useful in the treatment of pain.
  • Patent: US 6,887,978 B2: UNITED STATES OF AMERICA, 2005
    Status: Granted
    Registered in names of (Inventors): Peter McIntyre and Iain Fraser James
    Description of patent: Cloning of human TRPV1.
    Status: Awarded (PCT)
    Registered in names of (Inventors): Patapoutian A, Song S, Ganju P, Peier A, McIntyre P and Bevan S
    Description of patent: Novel genes and peptides and pain specific genes, including TRP family protein genes, expressed in sensory nerves and genes and polypeptides useful in the treatment of pain.
  • Patent: US 6,406,908 B1: UNITED STATES OF AMERICA, 2002
    Status: Granted
    Registered in names of (Inventors): Peter McIntyre and Iain Fraser James
    Description of patent: Cloning and use of the human TRPV1 receptor.